%PDF-1.4
%
88 0 obj
<>
endobj
85 0 obj
<>
endobj
175 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T15:33:51Z
2024-03-28T22:02:02-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T22:02:02-07:00
application/pdf
Heather
2001-1026.nov02
uuid:6e23709e-1dd2-11b2-0a00-9009275d6100
uuid:6e2370a0-1dd2-11b2-0a00-aa0000000000
endstream
endobj
74 0 obj
<>
endobj
75 0 obj
<>
endobj
89 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
38 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
49 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
207 0 obj
[211 0 R]
endobj
208 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
8 0 0 8 74.4 714.5293 Tm
(1998;9:721-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Schif)17.7 (ferli JA, Ng )36.7 (YC, Peters DK. )17.7 (The role of complement and its)]TJ
0 Tc 2.175 -1.25 Td
(receptor in the elimination of immune complexes. N Engl J Med)Tj
0 Tw 0 -1.25 TD
(1986;315:488-95.)Tj
0.0249 Tw -2.175 -1.25 Td
[(17.)-875 (Carroll MC. )17.7 (The role of complement and complement receptors in)]TJ
2.175 -1.25 Td
[(induction and regulation of immunity)64.9 (. )54.9 (Annu Rev Immunol)]TJ
0 Tw T*
(1998;16:545-68.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (T)34.8 (raustadottir KH, Steinsson K, Erlendsson K. C4AQ0 )]TJ
0 Tc 2.175 -1.25 Td
(superimposed on a primary defect increases the susceptibility to)Tj
-0.00011 Tc T*
(systemic lupus erythematosus \(SLE\) in a family with association)Tj
0 Tc T*
[(between C4AQ0 and SLE. J Rheumatol 1998;25:21)36.9 (18-25.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (T)69.7 (an EM, Cohen )54.8 (A, Fries J, et al. )17.7 (The revised criteria for the )]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Milford-W)79.8 (ard )54.9 (A. Proteins in plasma and body fluids.)]TJ
2.175 -1.25 Td
[(Electroimmunodif)17.8 (fusion. In: )17.7 (Thompson RA, editor)54.9 (. )17.7 (T)69.8 (echniques in)]TJ
T*
[(clinical immunology)64.9 (. London: Blackwell Scientific; 1981:9.)]TJ
-2.175 -1.25 Td
[(21.)-875 (Sim E, Cross SJ. Phenotyping of human complement component)]TJ
2.175 -1.25 Td
[(C4, a class-III HLA)-220.1 (antigen. Biochem J 1986;239:763-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Moulds JM, )54.8 (Arnett FC, Giles CG, Hamilton RG. )54.8 (A)-219.9 (novel)]TJ
0 Tc 2.175 -1.25 Td
(immunoassay for the quantitation of human C4 gene products.)Tj
T*
(Complement Inflamm 1990;7:95-101.)Tj
-2.175 -1.25 Td
[(23.)-875 (Moulds JM, )17.7 (W)79.8 (arner NB, )54.8 (Arnett FC. Complement component C4A)]TJ
2.175 -1.25 Td
(and C4B levels in systemic lupus erythematosus: Quantitation in)Tj
T*
[(relation to C4 null status and disease activity)64.9 (. J Rheumatol)]TJ
0 Tw T*
(1993;20:443-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Rafnar BO, )17.7 (T)34.8 (raustadottir KH, Sigfusson )54.8 (A, et al. )54.8 (An enzyme based)]TJ
0 Tc 2.175 -1.25 Td
(assay for the measurement of complement mediated binding of)Tj
T*
(immune complexes to red blood cells. J Immunol Methods)Tj
0 Tw T*
[(1998;21)36.9 (1:171-81.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Brandslund I, Siersted HC, Jensenius JC, Svehag SE. Detection and)]TJ
0 Tc 2.175 -1.25 Td
(quantitation of immune complexes with a rapid polyethylene glycol)Tj
T*
(precipitation complement consumption method \(PEG-CC\).)Tj
T*
(Methods Enzymol 1981;74:551-71.)Tj
-2.175 -1.25 Td
[(26.)-875 (Arason GJ, D\222Ambrogio MS, )17.7 (V)60.1 (ikingsdottir )17.7 (T)74 (, et al. Enzyme)]TJ
2.175 -1.25 Td
(immunoassays for measuring complement-dependent prevention of)Tj
T*
(immune precipitation and solubilization of preformed )Tj
T*
(antigen-antibody complexes. J Immunol Methods 1999;223:37-46.)Tj
-2.175 -1.25 Td
[(27.)-875 (Lachmann PJ. Complement deficiency and the pathogenesis of)]TJ
2.175 -1.25 Td
(autoimmune immune complex disease. Chem Immunol)Tj
0 Tw T*
(1990;49:245-63.)Tj
0.0249 Tw 30.825 50 Td
[(28.)-875 (Davies KA, Schif)17.8 (ferli JA, )17.7 (W)79.8 (alport MJ. Complement deficiency and)]TJ
2.175 -1.25 Td
(immune complex disease. Springer Semin Immunopathol)Tj
0 Tw T*
(1994;15:397-416.)Tj
0.0249 Tw -2.175 -1.25 Td
[(29.)-875 (Davies KA, Peters )54.8 (AM, Beynon HL, )17.7 (W)79.8 (alport MJ. Immune complex)]TJ
2.175 -1.25 Td
(processing in patients with systemic lupus erythematosus. In vivo)Tj
T*
(imaging and clearance studies. J Clin Invest 1992;90:2075-83.)Tj
-2.175 -1.25 Td
[(30.)-875 (Davies KA, Erlendsson K, Beynon HL, et al. Splenic uptake of)]TJ
2.175 -1.25 Td
(immune complexes in man is complement-dependent. J Immunol)Tj
0 Tw T*
(1993;151:3866-73.)Tj
0.0249 Tw -2.175 -1.25 Td
[(31.)-875 (W)79.8 (a)0.1 (lport MJ, Davies KA, Morley BJ, Botto M. Complement )]TJ
2.175 -1.25 Td
[(deficiency and autoimmunity)64.9 (. )54.8 (Ann NY)-183.2 (Acad Sci 1997;815:267-81.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Klickstein LB, Barbashov SF)79.8 (, Liu )17.7 (T)74 (, et al. Complement receptor)]TJ
2.175 -1.25 Td
(type 1 \(CR1, CD35\) is a receptor for C1q. Immunity 1997;)Tj
0 Tw T*
(7:345-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (T)69.7 (as SW)91.7 (, Klickstein LB, Barbashov SF)79.7 (, Nicholson-W)79.7 (eller )54.8 (A. C1q)]TJ
0 Tc 2.175 -1.25 Td
(and C4b bind simultaneously to CR1 and additively support)Tj
T*
(erythrocyte adhesion. J Immunol 1999;163:5056-63.)Tj
-2.175 -1.25 Td
[(34.)-875 (Schif)17.8 (ferli JA, Peters DK. Complement, the immune-complex)]TJ
2.175 -1.25 Td
(lattice, and the pathophysiology of complement-deficiency)Tj
T*
(syndromes. Lancet 1983;2:957-9.)Tj
-2.175 -1.25 Td
[(35.)-875 (Whaley K, )54.9 (Ahmed )54.9 (AE. Control of immune complexes by the)]TJ
2.175 -1.25 Td
[(classical pathway)64.9 (. Behring Inst Mitt 1989;84:1)36.9 (1)36.9 (1-20.)]TJ
-2.175 -1.25 Td
[(36.)-875 (W)79.8 (elch )17.8 (TR, Beischel L, Berry )54.9 (A, et al. )17.8 (The ef)17.8 (fect of null C4 alleles)]TJ
2.175 -1.25 Td
(on complement function. Clin Immunol Immunopathol)Tj
0 Tw T*
(1985;34:316-25.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Erlendsson K, )17.7 (T)34.8 (raustad\363ttir K, Freysd\363ttir J, Steinsson K, J\363nsd\363ttir)]TJ
0 Tc 2.175 -1.25 Td
[(I, )17.8 (V)111.1 (aldimarson H. Reciprocal changes in complement activity and)]TJ
T*
(immune-complex levels during plasma infusion in a C2-deficient)Tj
T*
(SLE patient. Lupus 1993;2:161-5.)Tj
-2.175 -1.25 Td
[(38.)-875 (Drake CG, Kotzin BL. Genetic and immunological mechanisms in)]TJ
2.175 -1.25 Td
(the pathogenesis of systemic lupus erythematosus. Curr Opin)Tj
T*
(Immunol 1992;4:733-40.)Tj
-2.175 -1.25 Td
[(39.)-875 (Briggs D, Stephens C, )17.7 (V)111.1 (aughan R, et al. )54.8 (A)-219.8 (molecular and serologic)]TJ
2.175 -1.25 Td
(analysis of the major histocompatibility complex and complement)Tj
T*
[(component C4 in systemic sclerosis. )54.9 (Arthritis Rheum 1993;)]TJ
0 Tw T*
(36:943-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Moriuchi J, Ichikawa )36.8 (Y)129.1 (,)-0.1 ( )17.7 (T)69.7 (akaya M, et al. )54.8 (Association of the)]TJ
0 Tc 2.175 -1.25 Td
[(complement allele C4AQ0 with primary Sjogren\222)54.9 (s syndrome in)]TJ
T*
[(Japanese patients. )54.9 (Arthritis Rheum 1991;34:224-7.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2002; 29:1)74 (1)]TJ
0 Tw -45.8691 -0.0313 Td
(2366)Tj
ET
0 0 0 0 scn
/GS0 gs
100.28 59.75 407.5 -10.83 re
f*
0.5 w
100.28 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
127 0 obj
<>
endobj
181 0 obj
<>
endobj
96 0 obj
<>
endobj
91 0 obj
<>
endobj
93 0 obj
<>
endobj
121 0 obj
<>stream
HVpMg}9ބ(ysHInB